;
Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • Selumetinib: Phase II data

    Array BioPharma Inc. (NASDAQ:ARRY), Boulder, Colo. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Selumetinib (ARRY-886, AZD6244) Business: Cancer Molecular target: MEK Description: Small molecule MEK …

    Published on 8/18/2014
  • Teysuno tegafur/gimeracil/oteracil potassium: Phase III data

    Taiho Pharmaceutical Co. Ltd., Tokyo, Japan Product: Teysuno tegafur/gimeracil/oteracil potassium (S-1, TS-1) Business: Cancer Molecular target: Dihydropyrimidine dehydrogenase Description: Oral combination of 5-…

    Published on 8/18/2014
  • BIL-010t: Phase I data

    Biosceptre International Ltd., Cambridge, U.K. Product: BIL-010t (formerly Topical Ointment for Skin Cancer (BSCT)) Business: Cancer Molecular target: Non-functioning P2X7 receptor (nfP2X7) Description: Topical purified…

    Published on 8/11/2014
  • Brodalumab: Extension study data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Brodalumab (KHK4827) (formerly AMG 827) Business: …

    Published on 8/11/2014
  • CAP-1002: Phase I/II data

    Capricor Therapeutics Inc. (OTCQB:CAPR), Beverly Hills, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: CAP-1002 Business: Cardiovascular Molecular target: NA Description: Allogeneic cardiosphere-…

    Published on 8/11/2014
  • DS107G: Phase I data

    Dignity Sciences Ltd., Dublin, Ireland Product: DS107G (Oral DGLA) Business: Dermatology Molecular target: NA Description: Oral formulation of a semi-synthetic derivative of dihomo-gamma-linolenic acid, an omega-6 fatty…

    Published on 8/11/2014
  • Egalet-001: Clinical trial data

    Egalet Corp. (NASDAQ:EGLT), Wayne, Pa. Product: Egalet-001 Business: Neurology Molecular target: Mu opioid receptor (OPRM1) (MOR) Description: Abuse-deterrent, extended-release, oral formulation of morphine Indication: …

    Published on 8/11/2014
  • Femara letrozole: Phase III data

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Femara letrozole Business: Genitourinary Molecular target: Aromatase Description: Aromatase inhibitor Indication: Treat infertility in women with polycystic …

    Published on 8/11/2014
  • FG-3019: Additional Phase I/II data

    FibroGen Inc., San Francisco, Calif. Product: FG-3019 Business: Cancer Molecular target: Connective tissue growth factor (CTGF) Description: Human mAb against connective tissue growth factor (CTGF) Indication: Treat …

    Published on 8/11/2014
  • GEN-004: Phase I data

    Genocea Biosciences Inc. (NASDAQ:GNCA), Cambridge, Mass. Product: GEN-004 Business: Infectious Molecular target: NA Description: T cell vaccine against ~Streptococcus pneumoniae containing SP0148, SP1912 and SP2108 …

    Published on 8/11/2014
  • GS-6615: Phase I data

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Product: GS-6615 Business: Cardiovascular Molecular target: NA Description: Selective late sodium current inhibitor Indication: Treat long QT3 syndrome (LQT3) …

    Published on 8/11/2014
  • GSK2586184: Development discontinued

    Galapagos N.V. (Euronext:GLPG; Pink:GLPYY), Mechelen, Belgium GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: GSK2586184 (formerly GLPG0778) Business: Autoimmune Molecular target: Janus kinase-1 (JAK-1) …

    Published on 8/11/2014
  • Halofuginone: Preliminary Phase Ib/IIa data

    Akashi Therapeutics Inc., Cambridge, Mass. Product: Halofuginone (HT-100) Business: Musculoskeletal Molecular target: Collagen type I (COL1) Description: Oral delayed-release formulation of halofuginone, a collagen type…

    Published on 8/11/2014
  • ICT-107: Additional Phase II data

    ImmunoCellular Therapeutics Ltd. (NYSE-M:IMUC), Calabasas, Calif. Product: ICT-107 Business: Cancer Molecular target: Dendritic cells Description: Intradermal dendritic cell-based therapeutic vaccine that targets 6 …

    Published on 8/11/2014
  • ISIS-GCGRRx: Phase II final data

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. Product: ISIS-GCGRRx Business: Endocrine/Metabolic Molecular target: Glucagon receptor (GCGR) Description: Antisense inhibitor targeting glucagon receptor (GCGR)…

    Published on 8/11/2014
  • Kyprolis carfilzomib: Interim Phase III data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Product: Kyprolis carfilzomib (PR-171, ONO-7057) Business: Cancer Molecular target: Proteasome Description: …

    Published on 8/11/2014
  • Lasofoxifene: Phase I data

    Ligand Pharmaceuticals Inc. (NASDAQ:LGND), La Jolla, Calif. Product: Lasofoxifene (formerly Oporia) Business: Endocrine/Metabolic Molecular target: Estrogen receptor Description: Selective estrogen receptor modulator (…

    Published on 8/11/2014
  • Locilex pexiganan acetate: Phase I data

    Dipexium Pharmaceuticals Inc. (NASDAQ:DPRX), New York, N.Y. Product: Locilex pexiganan acetate (formerly Cytolex, MSI-78) Business: Infectious Molecular target: NA Description: 22-amino acid linear peptide with ability …

    Published on 8/11/2014
  • Muparfostat: Interim Phase III data

    Medigen Biotechnology Corp. (GreTai:3176), Taipei, Taiwan Progen Pharmaceuticals Ltd. (ASX:PGL; Pink:PGLA), Melbourne, Australia Product: Muparfostat (PI-88) Business: Cancer Molecular target: Vascular endothelial …

    Published on 8/11/2014
  • Oxycodone DETERx: Phase III data

    Collegium Pharmaceutical Inc., Canton, Mass. Product: Oxycodone DETERx (COL-003) Business: Neurology Molecular target: Opioid receptor (OPR) Description: Extended-release oral oxycodone formulated with DETERx tamper …

    Published on 8/11/2014
  • Resminostat: Phase I data

    4SC AG (Xetra:VSC), Planegg-Martinsried, Germany Yakult Honsha Co. Ltd. (Tokyo:2267), Tokyo, Japan Product: Resminostat (4SC-201) (formerly BYK408740) Business: Cancer Molecular target: Histone deacetylase (HDAC) …

    Published on 8/11/2014
  • Rivipansel: Phase II data

    GlycoMimetics Inc. (NASDAQ:GLYC), Gaithersburg, Md. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Rivipansel (GMI-1070, PF-06460031) Business: Hematology Molecular target: E selectin (SELE) (CD62E); P selectin (SELP)…

    Published on 8/11/2014
  • TGR-1202: Preliminary Phase I data

    Rhizen Pharmaceuticals S.A., La Chaux-de-Fonds, Switzerland TG Therapeutics Inc. (NASDAQ:TGTX), New York, N.Y. Product: TGR-1202 (formerly RP5264) Business: Cancer Molecular target: Phosphoinositide 3-kinase (PI3K) …

    Published on 8/11/2014
  • Ublituximab: Phase I/II data

    LFB S.A., Les Ulis, France TG Therapeutics Inc. (NASDAQ:TGTX), New York, N.Y. Ildong Pharmaceutical Co. Ltd. (KSE:000230), Seoul, South Korea Product: Ublituximab (TGTX-1101, TG-1101, LFB-R603) Business: Cancer …

    Published on 8/11/2014
  • Ublituximab: Preliminary Phase I data

    LFB S.A., Les Ulis, France TG Therapeutics Inc. (NASDAQ:TGTX), New York, N.Y. Ildong Pharmaceutical Co. Ltd. (KSE:000230), Seoul, South Korea Product: Ublituximab (TGTX-1101, TG-1101, LFB-R603) Business: Cancer …

    Published on 8/11/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993